NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free RGLS Stock Alerts $2.88 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.80▼$2.9250-Day Range$1.17▼$2.8852-Week Range$0.78▼$3.79Volume808,981 shsAverage Volume3.08 million shsMarket Capitalization$58.23 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Regulus Therapeutics alerts: Email Address Regulus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside151.7% Upside$7.25 Price TargetShort InterestBearish13.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 18 Articles This WeekInsider TradingSelling Shares$23,857 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.52) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector404th out of 938 stocksPharmaceutical Preparations Industry183rd out of 417 stocks 4.4 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.25, Regulus Therapeutics has a forecasted upside of 151.7% from its current price of $2.88.Amount of Analyst CoverageRegulus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.02% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regulus Therapeutics has recently increased by 9,244.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 3.1 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Regulus Therapeutics this week, compared to 1 article on an average week.Search Interest25 people have searched for RGLS on MarketBeat in the last 30 days. MarketBeat Follows16 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,857.00 in company stock.Percentage Held by InsidersOnly 8.41% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.52) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Regulus Therapeutics Stock (NASDAQ:RGLS)Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesMarch 28, 2024 | markets.businessinsider.comBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment NeedsMarch 28, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Up 9,244.3% in MarchMarch 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 27, 2024 | americanbankingnews.comHC Wainwright Comments on Regulus Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:RGLS)March 26, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Rating Reiterated by HC WainwrightMarch 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development MilestonesMarch 23, 2024 | finance.yahoo.comRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical AdvancementsMarch 23, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.comMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 22, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 21, 2024 | investorplace.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023March 21, 2024 | finance.yahoo.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 21, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Given New $11.00 Price Target at Canaccord Genuity GroupMarch 21, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives $7.50 Consensus Price Target from BrokeragesMarch 20, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Regulus Therapeutics Inc. Increased by Analyst (NASDAQ:RGLS)March 20, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Expected to Post FY2023 Earnings of ($1.60) Per ShareMarch 20, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Receives "Outperform" Rating from Leerink PartnrsMarch 20, 2024 | americanbankingnews.comAnalysts Set Expectations for Regulus Therapeutics Inc.'s FY2025 Earnings (NASDAQ:RGLS)March 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment DataMarch 19, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Given Buy Rating at HC WainwrightMarch 19, 2024 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at SVB LeerinkMarch 15, 2024 | finance.yahoo.comRGLS Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & MoreMarch 13, 2024 | markets.businessinsider.comRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial PositionMarch 12, 2024 | marketwatch.comRegulus Therapeutics Shares Soar on Funding, Study DataMarch 12, 2024 | markets.businessinsider.comRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 MlnMarch 12, 2024 | msn.comWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?See More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$7.25 High Stock Price Target$11.00 Low Stock Price Target$3.00 Potential Upside/Downside+151.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.21% Return on Assets-80.55% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book2.74Miscellaneous Outstanding Shares20,220,000Free Float18,522,000Market Cap$58.23 million OptionableOptionable Beta1.45 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 55)CEO & Director Comp: $920.73kMs. Crispina Calsada CPA (Age 54)Chief Financial Officer Comp: $500.87kMr. Christopher Ray Aker J.D. (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $524.79kDr. Preston S. Klassen M.D. (Age 55)M.H.S., President, Head of Research & Development and Director Mr. Daniel J. Penksa (Age 38)VP of Finance & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Senior Vice President of Clinical OperationsDr. Rekha Garg M.D.M.S., Senior Vice President of Clinical Development & RegulatoryMr. Edmund Lee Ph.D.Vice President of Translational MedicineMore ExecutivesKey CompetitorsLeap TherapeuticsNASDAQ:LPTXCidara TherapeuticsNASDAQ:CDTXCellectar BiosciencesNASDAQ:CLRBInflaRxNASDAQ:IFRXDyadic InternationalNASDAQ:DYAIView All CompetitorsInsiders & InstitutionsExome Asset Management LLCBought 178,404 shares on 2/15/2024Ownership: 0.882%Citadel Advisors LLCBought 2,000 shares on 2/15/2024Ownership: 0.000%Victory Capital Management Inc.Bought 38,529 shares on 2/5/2024Ownership: 1.344%Joseph P HaganSold 14,580 sharesTotal: $17,350.20 ($1.19/share)Crispina CalsadaSold 5,468 sharesTotal: $6,506.92 ($1.19/share)View All Insider TransactionsView All Institutional Transactions RGLS Stock Analysis - Frequently Asked Questions Should I buy or sell Regulus Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks. What is Regulus Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued twelve-month price objectives for Regulus Therapeutics' shares. Their RGLS share price targets range from $3.00 to $11.00. On average, they anticipate the company's share price to reach $7.25 in the next twelve months. This suggests a possible upside of 151.7% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts. How have RGLS shares performed in 2024? Regulus Therapeutics' stock was trading at $1.28 at the beginning of 2024. Since then, RGLS shares have increased by 125.0% and is now trading at $2.88. View the best growth stocks for 2024 here. Are investors shorting Regulus Therapeutics? Regulus Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 5,130,000 shares, an increase of 9,244.3% from the February 29th total of 54,900 shares. Based on an average daily volume of 2,870,000 shares, the short-interest ratio is presently 1.8 days. Currently, 13.0% of the shares of the stock are short sold. View Regulus Therapeutics' Short Interest. When is Regulus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RGLS earnings forecast. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings data on Thursday, March, 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). When did Regulus Therapeutics' stock split? Regulus Therapeutics's stock reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN). Who are Regulus Therapeutics' major shareholders? Regulus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (1.34%), Exome Asset Management LLC (0.88%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Ray Aker, Crispina Calsada, Denis Drygin and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RGLS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.